Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
Norouzi S, Javinani A, Aminorroaya A, Masoumi M. Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis. BMC Cardiovascular Disorders 2020, 20: 390. PMID: 32847506, PMCID: PMC7448352, DOI: 10.1186/s12872-020-01676-x.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCardiac systolic dysfunctionCardiovascular diseaseSystolic dysfunctionRheumatoid arthritisReduced left ventricular ejection fractionPredictors of left ventricular ejection fractionAnti-modified citrullinated vimentinEchocardiographic parameters of systolicDisease Activity Score-28Anti-MCV levelsParameters of systolicAssociation of autoantibodiesVentricular ejection fractionConcomitant cardiovascular diseaseExclusion of patientsSusceptibility to cardiovascular diseaseReceiver operating characteristic curveDuration of diseaseCardiovascular disease risk factorsAnti-citrullinated proteinFramingham risk scoreCross-sectional studyTransthoracic echocardiographyDiastolic dysfunction